Direct Oral Anticoagulant (DOAC) switching programme

The Direct Oral Anticoagulant (DOAC) switching programme reviews the prescribing of direct oral anticoagulants for people with non-valvular atrial fibrillation to ensure treatment is safe, effective and consistent across the system.

The programme includes a structured clinical review of relevant factors such as kidney function, body weight, risk scores and current medicines. Where appropriate, this review may result in a switch from edoxaban to apixaban in line with agreed national and local clinical guidance.

The programme supports improved safety and standardisation of care while enabling more efficient use of NHS resources.